ArticleScientific reports2026
Insight into the potential significance of miR-760 and miR-1973 in breast cancer: a comprehensive analysis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant expression levels of miR-760 and miR-1973 were observed in different solid tumors; however, their expression levels in breast cancer (BC) remain unclear. This study aimed to evaluate their expression levels, assess their relationship with the clinicopathological features, and explore their molecular mechanisms using bioinformatic analysis. MiRNAs’ expression levels and CA 15.3 concentration were measured in 130 patients and 30 healthy controls. Databases were used to predict their target genes, functional enrichment analyses were carried out, and PPI network was constructed. Additionally, the Kaplan-Meier (KM) plotter online database was utilized for survival analysis. Both miRNAs’ levels were significantly overexpressed in BC patients and more pronounced in the early stage. Further, the diagnostic abilities of miR-760 and miR-1973 were superior in discriminating BC patients than CA 15.3. These miRNAs were associated with increased susceptibility to BC. Based on bioinformatic analysis, 4 hub genes were identified and implicated in significant signaling pathways in BC. KM plotter demonstrated that BC patients with overexpressed miR-760 had shorter overall survival. In conclusion, this study provides novel insights into the clinical utility of miR-760 and miR-1973 as non-invasive biomarkers for BC and sheds light on their important contribution to BC pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.